Product/Composition:- | Trastuzumab |
---|---|
Strength:- | IV : 150 mg/ 7.5 mL (vial); SQ: 600 mg/ 5 mL (syringe) |
Form:- | IV & SQ Injection |
Reference Brands:- | Herceptin® (EU & US); Herceptin Hylecta® (subcutaneous formulation) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Trastuzumab (Herceptin®) is a monoclonal antibody used to treat HER2-positive breast and gastric cancer. It targets the HER2 receptor, inhibiting cancer cell growth. Available in intravenous (IV) and subcutaneous (SC) formulations, it comes in 150 mg vials (IV) and 600 mg syringes (SC). Widely used in combination therapy, it improves outcomes for HER2-positive cancers in both the US and EU.
Trastuzumab is a monoclonal antibody used in oncology, primarily for the treatment of HER2-positive breast cancer and gastric cancer. It works by targeting the HER2 receptor, a protein that is overexpressed in some cancer cells, blocking its signaling and inhibiting cancer cell growth. Available as Herceptin® in both the US and EU, Trastuzumab is offered in intravenous (IV) and subcutaneous (SC) formulations. The IV formulation is commonly administered in 150 mg vials, while the SC formulation is available in 600 mg syringes. Used as part of combination therapy, it improves patient outcomes in HER2-positive cancers.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications